יחס חוב כולל להון עצמי Creative Medical Technology Holdings Inc. (CELZ)

Creative Medical Technology (CELZ) specializes in regenerative male health treatments utilizing AmnioStem cellular products. This price chart from GURU.Markets demonstrates a debt-to-equity ratio of 0.00. The company's monopoly pricing power is bolstered by the implementation of automated bioreactors to eliminate human error, as well as the ownership of unique patents in the field of immunomodulation.

To minimize capital loss risks amid volatility, investors must analyze the total debt-to-equity ratio, which measures the proportion of borrowed funds relative to the company's own resources to assess financial leverage. This metric determines the balance sheet resilience of Creative Medical Technology (CELZ) to rising Fed rates, which is critical for a venture business in the non-cyclical cell therapy sector.